Essential Partners
KNSA icon

Essential Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Essential Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$51K Hold
684
– – 0.02% 606
2026
Q2 		$43.7K Sell
684
-1,242
-64% -$64.4K 0.02% 647
2026
Q1 		$92.7K Hold
1,926
– – 0.03% 437
2025
Q4 		$79.4K Buy
1,926
+3
+0.2% +$120 0.02% 502
2025
Q3 		$74.7K Buy
1,923
+1
+0.1% +$32 0.02% 493
2025
Q2 		$53.2K Buy
+1,922
New +$48.9K 0.02% 461

Other funds holding KNSA

Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Linden Thomas Advisory Services
Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Sowell Financial Services
Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
Juncture Wealth Strategies
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Essential Partners's KNSA Position: Q3 2026 in Review

Essential Partners held its Kiniksa Pharmaceuticals (KNSA) position steady in Q3 2026 at 684 shares worth $51K. The position accounts for 0.02% of the portfolio, ranked #606.

Essential Partners first reported a position in KNSA in Q2 2025 and has held it in 6 quarters since. The position peaked at $92.7K in Q1 2026. 40 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Essential Partners held 684 shares of Kiniksa Pharmaceuticals worth $51K as of Q3 2026.
  • Essential Partners left its Kiniksa Pharmaceuticals share count unchanged in Q3 2026.
  • Kiniksa Pharmaceuticals made up 0.02% of Essential Partners's portfolio in Q3 2026, its #606 holding.
  • Essential Partners first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Kiniksa Pharmaceuticals position peaked at $92.7K in Q1 2026.
  • 40 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.